NICM
XENE icon

Neo Ivy Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Neo Ivy Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,710
Closed -$797K – 513
2026
Q1 		$797K Buy
13,710
+6,233
+83% +$287K 0.21% 173
2025
Q4 		$335K Sell
7,477
-42,361
-85% -$1.78M 0.05% 224
2025
Q3 		$2M Buy
+49,838
New +$1.76M 0.49% 71

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Neo Ivy Capital Management's XENE Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 13,710 shares — an estimated $797K sold.

Neo Ivy Capital Management first reported a position in XENE in Q3 2025 and held it in 3 quarters. The position peaked at $2M in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 13,710 Xenon Pharmaceuticals shares in Q2 2026, an estimated $797K.
  • Neo Ivy Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Neo Ivy Capital Management's Xenon Pharmaceuticals position peaked at $2M in Q3 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.